BMC Clinical Pathology

Table 1 Clinical features and SOX2 antibody and protein staining characteristics of SCLC patients

From: Autologous anti-SOX2 antibody responses reflect intensity but not frequency of antigen expression in small cell lung cancer

		n	Median survival (months)	P (log rank)
Age	61 (44–78)
	<60	24	10.36	0.76
	≥60	35	7.1	0.76
LDH	193 IU/L (133–380)
	<200	30	10.75	0.36
	≥200	25	8.86	0.36
	U*	4
AP	93 IU/L (50-171
	<70	14	3.97	0.47
	≥70	44	8.68	0.47
	U	1
Stage	Limited	28	10.36	0.03
	Extensive	27	7.34	0.03
	U	1
SOX2 antibody	<M + 2SD	42	8.68	0.3
	≥ M + 2SD	17	7.85	0.3
SOX2 IHC intensity**	0-1	25	7.39	0.98
	2-3	30	10.65	0.98
SOX2 IHC frequency	<5 %	16	25.87	0.12
	≥5 %	39	7.39	0.12
SOX2 IHC frequency	<20 %	24	7.4	0.11
	≥20 %	31	7.86	0.11
SOX2 IHC frequency	<40 %	29	7.39	0.43
	≥40 %	26	9.68	0.43

*U: unknown. **Tumor tissue sections evaluations were available from 55 patients.

Back to article page

ISSN: 1472-6890

Contact us

General enquiries: ORSupport@springernature.com